Dhoble Abhijeet, Bhise Viraj, Nevah Moises I, Balan Prakash, Nguyen Tom C, Estrera Anthony L, Smalling Richard W
Division of Cardiology, University of Texas McGovern Medical School, Houston, Texas.
Memorial Herman Heart and Vascular Center, Texas Medical Center, Houston, Texas.
Catheter Cardiovasc Interv. 2018 Jan 1;91(1):90-96. doi: 10.1002/ccd.27232. Epub 2017 Aug 28.
The data on the comparative outcomes and readmissions after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with cirrhosis are limited. We compared mortality, complications, discharge disposition, 30-day readmission rates, length of stay, and cost of hospitalization in cirrhotic patients undergoing TAVR and SAVR.
The National Inpatient Sample (NIS) and the National Readmission Database (NRD) were used for the study. The International Classification of Diseases-9th version was used to define cohorts of patients undergoing TAVR and SAVR. Patients undergoing concomitant other valve or coronary bypass surgery were excluded. Propensity-score matching was used to compare the outcomes between the groups.
From 2012 to 2014, a total of 126 and 157 patients with cirrhosis underwent TAVR and SAVR, respectively. Of the 283 patients, 16 (5.7%) died during the same hospitalization. We found 345 patients with cirrhosis who had undergone an aortic valve replacement (156 with TAVR, and 189 with SAVR) in the 2013 and 2014 NRD. On propensity matching, there were no significant differences between the in-hospital mortality, readmissions, hospitalization costs, and discharges to home within the TAVR and SAVR groups. However, post-procedure length of stay (6.3 vs. 10.2 days; P < 0.001) and blood transfusion rates (22% vs. 58%; P < 0.001) were significantly lower in TAVR patients.
Cirrhotic patients undergoing TAVR has high, but similar mortality and 30-day readmission rates when compared to SAVR; however, has shorter length of stay and lower blood transfusion rates.
关于肝硬化患者经导管主动脉瓣置换术(TAVR)和外科主动脉瓣置换术(SAVR)后的比较结果及再入院情况的数据有限。我们比较了接受TAVR和SAVR的肝硬化患者的死亡率、并发症、出院处置、30天再入院率、住院时间和住院费用。
本研究使用了国家住院样本(NIS)和国家再入院数据库(NRD)。采用国际疾病分类第九版来定义接受TAVR和SAVR的患者队列。排除同时接受其他瓣膜或冠状动脉搭桥手术的患者。使用倾向评分匹配法比较两组之间的结果。
2012年至2014年,分别有126例和157例肝硬化患者接受了TAVR和SAVR。在这283例患者中,16例(5.7%)在同一住院期间死亡。我们在2013年和2014年的NRD中发现了345例接受主动脉瓣置换术的肝硬化患者(156例接受TAVR,189例接受SAVR)。经倾向匹配后,TAVR组和SAVR组在院内死亡率、再入院率、住院费用和回家出院方面没有显著差异。然而,TAVR患者术后住院时间(6.3天对10.2天;P<0.001)和输血率(22%对58%;P<0.001)显著更低。
与SAVR相比,接受TAVR的肝硬化患者死亡率和30天再入院率虽高但相似;然而,其住院时间更短,输血率更低。